Content about Transdermal patches

January 30, 2013
Estrogen patch, described as smallest, available at pharmacies

A patch for treating menopause that the manufacturer calls the smallest is now available.

NEW YORK — A patch for treating menopause that the manufacturer calls the smallest is now available.

Noven Pharmaceuticals announced the availability of Minivelle (estradiol) transdermal system in pharmacies. The patch, which the Food and Drug Administration approved in October 2012, is designed for treating hot flashes and night sweats in women with menopause.

The patch has a surface area nearly the same as a dime at its lowest strength of 0.0375 mg-per-day and is 34% smaller than Noven's Vivelle-Dot patch, the company said.

December 29, 2011
Sam's Club unveils New Year's resolutions-based health screenings program

To help its members keep their New Year's resolutions, including weight loss, eating better and quitting smoking, Sam's Club will offer a variety of free in-club health screenings and smoking-cessation consultations.

BENTONVILLE, Ark. — To help its members keep their New Year's resolutions, including weight loss, eating better and quitting smoking, Sam's Club will offer a variety of free in-club health screenings and smoking-cessation consultations.

March 2, 2011
Drug makers file suit against Mylan over generic Vivelle-Dot

A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

PITTSBURGH — A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

February 11, 2011
Mallinckrodt receives FDA approval for generic Duragesic

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

ST. LOUIS — The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

Mallinckrodt, part of Covidien, said the FDA approved its fentanyl transdermal system patch.

The patch is a generic version of Johnson & Johnson’s Duragesic. The drug, an opioid and Class II controlled substance, is used for managing persistent, moderate-to-severe pain that requires continuous opioid administration.

October 27, 2010
GSK Consumer Healthcare applauds FDA's workshop on NRT products

GlaxoSmithKline Consumer Healthcare on Thursday commended the Food and Drug Administration for holding a scientific...

PARSIPPANY, N.J. GlaxoSmithKline Consumer Healthcare on Thursday commended the Food and Drug Administration for holding a scientific workshop this week that focused on the risks and benefits associated with the long-term use of nicotine-replacement therapy products.

 

February 1, 2010
Study finds full use of nicotine-patch therapy may prevent relapse

Future ex-smokers who utilize a nicotine-patch therapy longer may be less likely to relapse, according...